Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: J Pain. 2014 Jun 9;15(9):907–914. doi: 10.1016/j.jpain.2014.05.008

Figure 1.

Figure 1

Repeated administration of t-TUCB relieves diabetic neuropathy in the CPP assay. Increasing the dose of t-TUCB results in a clear dose response relationship in the CPP assay depicted as the change in time (test-preconditioning) spent in the drug paired chamber. The 10 mg/kg/day dose of t-TUCB significantly increases the conditioned place preference for the drug paired chamber (* p= 0.008). The positive control gabapentin (100 mg/kg/day) induces a drug-paired chamber preference compared to the vehicle (# p= 0.040). However, the 10 mg/kg/day dose of t-TUCB outperformed the positive control gabapentin at 10 fold lower dose.